Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Society
04 November 2008 - 11:00PM
PR Newswire (US)
JERUSALEM, November 4 /PRNewswire-FirstCall/ -- Oramed
Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com/), a
developer of proprietary drug delivery systems, announced today
that its poster entitled "Enteral Administration of Exenatide-4;
Proof of Concept Pharmacodynamic Study in Dogs," has been accepted
for presentation at the Diabetes Technology Society's Eighth Annual
Meeting in Bethesda, Maryland between November 13-15, 2008.
Oramed's exploratory study of enteral delivery of GLP-1 analog,
exenatide-4, an incretin mimetic with antihyperglycemic actions on
dogs, advances research in the area of enteral delivery of
polypeptides and proteins. Oramed's test results showed that direct
instillation of GLP-1 analog significantly curbed post-glucose
loading, demonstrating the feasibility of administering the drug
enterally. "The selection of Oramed as one of the companies to
present at the Diabetes Technology Conference is a wonderful
opportunity for us to demonstrate our revolutionary technology to
the world's leading diabetes scientists," said Nadav Kidron, Oramed
CEO. "We are very proud that our research is advancing the
treatment of diabetes and we look forward to continuing to present
strong results from the studies and trials we are currently
conducting." Oramed's abstract will be presented on Thursday,
November 13, from 6-8 PM. The poster will be available for viewing
throughout the conference. For more information about the Diabetes
Technology Society's Eighth Annual Meeting, please visit
http://www.diabetestechnology.org/index.html For more information
about Oramed Pharmaceuticals, please visit
http//http://www.oramed.com/ About Oramed Pharmaceuticals Oramed
Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via
injection. Oramed is seeking to revolutionize the treatment of
diabetes through its patented flagship product, an orally
ingestible insulin capsule currently in phase 2 clinical trials.
Established in 2006, Oramed's technology is based on over 25 years
of research by top research scientists at Jerusalem's Hadassah
Medical Center. The Company's corporate and R&D headquarters
are based in Jerusalem. For more information, please visit
http://www.oramed.com/ Forward-looking statements Some of the
statements contained in this press release are forward-looking
statements which involve known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or
achievements of the company, or industry results, to be materially
different from any future results, performance or achievements
expressed or implied by such forward looking statements, including
the risks and uncertainties related to the progress, timing, cost,
and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our
product candidates; competition from other pharmaceutical or
biotechnology companies; and the company's ability to obtain
additional funding required to conduct its research, development
and commercialization activities. Please refer to the company's
filings with the Securities and Exchange Commission for a
comprehensive list of risk factors that could cause actual results,
performance or achievements of the company to differ materially
from those expressed or implied in such forward looking statements.
The company undertakes no obligation to update or revise any
forward-looking statements. Company and Investor Relation Contacts:
Oramed Pharmaceuticals Eric Rosenberg Cell: +972-54-566-7713
Office: +972-2-566-0001 Email: Media Contacts: Ruder Finn Israel
for Oramed Matthew Krieger Cell: +972-54-467-6950 Office:
+972-2-589-2003 Email: DATASOURCE: Oramed Pharmaceticals CONTACT:
Company and Investor Relation Contacts: Oramed Pharmaceuticals,
Eric Rosenberg, Cell: + 972-54-566-7713, Office: + 972-2-566-0001,
Email: ; Media Contacts: Ruder Finn Israel for Oramed, Matthew
Krieger, Cell: + 972-54-467-6950, Office: + 972-2-589-2003, Email:
Copyright